Wanpeng Yu

Prof. Wanpeng Yu


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
YXYingjie Xu
Yingjie Xu
YZYuan Zhang
Yuan Zhang
WYWanpeng Yu
Wanpeng Yu
Atherosclerosis (AS) is a chronic inflammatory disease that primarily affects large and medium-sized arteries and serves as the major pathological basis for cardiovascular diseases such as coronary heart disease. During the progression of AS, macrophages play a crucial role in promoting inflammatory regulation. Sustained local inflammatory responses are triggered by the accumulation of macrophages in arterial walls, which either promote or inhibit the development of AS by modulating inflammatory progression, plaque stability, and the surrounding immune microenvironment. Therefore, therapeutic strategies targeting macrophages and eliminating pro-inflammatory features in the plaque microenvironment hold promise as novel approaches to slow the progression of AS. With the deepening understanding of the mechanisms underlying AS, numerous innovative nanotherapeutic systems for its diagnosis and treatment have been developed. Here, we review strategies for designing novel nanosystems to treat AS, including modifying targeting ligands and utilizing biomimetic nanoparticles to enhance drug accumulation in target lesions and improve bioavailability. Macrophage-targeted nanotherapeutic approaches aim to reduce plaque burden and inflammation by regulating macrophage apoptosis, autophagy, and inducing efferocytosis synergistically. Concurrently, the development of intelligent responsive nanoparticles based on the inflammatory microenvironment enables targeted elimination of inflammatory characteristics within plaque microenvironments. These strategies demonstrate significant potential for application in AS treatment.

12 August 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
XLXiuyun Li
Xiuyun Li
HMHao Meng
Hao Meng
HWHefeng Wang
Hefeng Wang
YZYujing Zhang
Yujing Zhang
WYWanpeng Yu
Wanpeng Yu
Indoleamine 2,3-dioxygenase 1 (IDO1) has emerged as a critical immunometabolic regulator in cancer, orchestrating immunosuppression through its rate-limiting catabolism of tryptophan to kynurenine. This enzymatic activity establishes an immunosuppressive tumor microenvironment via two distinct pathways: GCN2-mediated T cell anergy resulting from tryptophan depletion, and AhR-dependent immune tolerance induced by accumulating kynurenine metabolites. The therapeutic landscape of IDO1 inhibition has progressed significantly from early heme-competitive inhibitors like epacadostat to next-generation proteolysis-targeting chimera (PROTAC) technology. While over 20 small-molecule IDO1 inhibitors have entered clinical trials for various cancers, their variable efficacy has underscored the need for improved target engagement strategies and better patient selection biomarkers. PROTACs represent a paradigm shift in IDO1 modulation, offering the unique advantage of complete target degradation rather than mere inhibition. This review systematically evaluates: (1) clinically investigated IDO1 inhibitors and their pharmacological profiles, and (2) the preclinical promise of IDO1-targeting PROTAC degraders. Through critical analysis of their mechanisms of action and therapeutic potential, we provide insights into optimizing IDO1-targeted strategies for cancer immunotherapy.

15 September 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
WJWenqing Jiang
Wenqing Jiang
XYXiaoping Yang
Xiaoping Yang
HLHuiying Liu
Huiying Liu
CWChao Wang
Chao Wang
HNHongxin Niu
Hongxin Niu
WYWanpeng Yu
Wanpeng Yu
The stimulator of interferon genes (STING) pathway is a central regulator of innate immunity, mediating host defense against pathogens but driving chronic inflammation when dysregulated-underpinning autoimmune diseases, fibrosis, and cancer. Traditional therapies targeting STING (e.g., small-molecule inhibitors, monoclonal antibodies) face limitations including incomplete pathway suppression, off-target effects, and reliance on continuous dosing. Proteolysis-targeting chimeras (PROTACs) offer a transformative approach by enabling selective degradation of STING, achieving sustained suppression of pathological signaling. However, critical gaps remain in understanding their selectivity for pathological vs. homeostatic STING activity, risks of immune suppression, and translational challenges. This review critically evaluates the rationale for STING degradation, with a comparative analysis of recent PROTAC designs (including warhead, E3 ligase, and linker optimization) and their pharmacokinetic/pharmacodynamic trade-offs. We address compensatory innate immune pathways, biomarker development hurdles, and safety risks, highlighting strategies to enhance specificity and clinical utility. STING-targeting PROTACs hold promise for inflammatory diseases, but their success depends on overcoming these challenges.

1 September 2025 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
XYXiaoping Yang
Xiaoping Yang
HNHongxin Niu
Hongxin Niu
WJWen Jiang
Wen Jiang
WYWanpeng Yu
Wanpeng Yu
WJWenqing Jiang
Wenqing Jiang
Chinese herbal medicines (CHMs) is the crystallization of wisdom accumulated by the Chinese nation over thousands of years. With the development and advancement of technology, extensive research has been conducted on the pharmacological activities of active components in CHMs. Natural constituents from medicinal plants exhibit rich scaffold diversity and structural complexity, playing crucial roles in the pharmacological effects of CHMs. However, many CHMs components have been found to suffer from poor water solubility, low stability, and limited bioavailability, which significantly restrict their clinical applications. In recent years, nanomedicine has been leveraging the power of nanotechnology to fully exploit its distinctive advantages. In the field of CHMs, the introduction of nanonization technology has enhanced the therapeutic efficacy of CHMs formulations. Especially the use of nano-modified CHMs solely derived from natural products has overcome several “bottlenecks” associated with chemical nanodelivery systems—such as insufficient drug loading, high production costs, potential systemic toxicity, and immunogenicity—emerging as an innovative and promising platform for disease treatment. Here, we review recent advancements in pharmaceutical nanotechnologies for CHMs in the treatment of pulmonary diseases and lung cancer. These nano-modified CHMs include nanoemulsions, self-assembled nanoparticles, nanocrystals, herbal-derived exosomes, and carbon dot-based nanozymes formulated from natural medicinal plants. They demonstrate unique advantages in enhancing the pharmacological effects of natural bioactive compounds and treating pulmonary disorders and lung cancer. This provides novel insights into the development of nano-modified CHMs in the treatment of pulmonary disease and lung cancer.